Literature DB >> 8995216

Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells.

A Hirai1, S Nakamura, Y Noguchi, T Yasuda, M Kitagawa, I Tatsuno, T Oeda, K Tahara, T Terano, S Narumiya, L D Kohn, Y Saito.   

Abstract

Cyclin-dependent kinase (Cdk) enzymes are activated for entry into the S phase of the cell cycle. Elimination of Cdk inhibitor protein p27Kip1 during the G1 to S phase is required for the activation process. An inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase prevents its elimination and leads to G1 arrest. Mevalonate and its metabolite, geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate, restore the inhibitory effect of pravastatin on the degradation of p27 and allow Cdk2 activation. By the addition of geranylgeranyl pyrophosphate, Rho small GTPase(s) are geranylgeranylated and translocated to membranes during G1/S progression. The restoring effect of geranylgeranyl pyrophosphate is abolished with botulinum C3 exoenzyme, which specifically inactivates Rho. These results indicate (i) among mevalonate metabolites, geranylgeranyl pyrophosphate is absolutely required for the elimination of p27 followed by Cdk2 activation; (ii) geranylgeranylated Rho small GTPase(s) promote the degradation of p27 during G1/S transition in FRTL-5 cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995216

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors.

Authors:  Madalina Musat; Márta Korbonits; Megan Pyle; Maria Gueorguiev; Blerina Kola; Damian G Morris; Michael Powell; Constantin Dumitrache; Catalina Poiana; Ashley B Grossman
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension.

Authors:  S Huang; C S Chen; D E Ingber
Journal:  Mol Biol Cell       Date:  1998-11       Impact factor: 4.138

3.  RhoG GTPase controls a pathway that independently activates Rac1 and Cdc42Hs.

Authors:  C Gauthier-Rouvière; E Vignal; M Mériane; P Roux; P Montcourier; P Fort
Journal:  Mol Biol Cell       Date:  1998-06       Impact factor: 4.138

4.  The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms.

Authors:  Daniel R Croft; Michael F Olson
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

5.  Ect2, an ortholog of Drosophila Pebble, regulates formation of growth cones in primary cortical neurons.

Authors:  Takahiro Tsuji; Chiharu Higashida; Yoshihiko Aoki; Mohammad Saharul Islam; Mitsuko Dohmoto; Haruhiro Higashida
Journal:  Neurochem Int       Date:  2012-02-15       Impact factor: 3.921

6.  Expression and significance of RhoC gene in hepatocellular carcinoma.

Authors:  Wei Wang; Lian-Yue Yang; Zhi-Li Yang; Gen-Wen Huang; Wei-Qun Lu
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 7.  p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Authors:  A Alkarain; R Jordan; J Slingerland
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

8.  p160ROCK mediates RhoA activation of Na-H exchange.

Authors:  T Tominaga; T Ishizaki; S Narumiya; D L Barber
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

9.  Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer.

Authors:  H Kawana; J Tamaru; T Tanaka; A Hirai; Y Saito; M Kitagawa; A Mikata; K Harigaya; T Kuriyama
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

10.  Effects of lovastatin on breast cancer cells: a proteo-metabonomic study.

Authors:  Jelena Klawitter; Touraj Shokati; Vanessa Moll; Uwe Christians; Jost Klawitter
Journal:  Breast Cancer Res       Date:  2010-03-05       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.